Biomarkers /
ATR
Overview
ATR serine/threonine kinase (ATR) is a gene that encodes a protein that is a member of the PI3/PI4-kinase family. The protein functions in the phosphorylation of checkpoint kinase CHK1, RAD17, RAD9, and tumor suppressor protein BRCA1 - proteins that are involved in the cell cycle and DNA damage signaling pathways. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
ATR is altered in 2.88% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].
The most common alterations in ATR are ATR Mutation (2.92%), ATR Nonsense (0.33%), ATR Frameshift (0.23%), ATR Amplification (0.23%), and ATR Fusion (0.13%) [3].
Clinical Trials
Significance of ATR in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.